Abstract: The invention relates to a method for determining the quality of an imaging plate, comprising the steps of carrying out an exposure of the imaging plate, carrying out a scan of the imaging plate in order to determine an image, determining a signal-to-noise ratio of the image or/and carrying out edge recognition on the image and calculating a quality value of the imaging plate on the basis of the signal-to-noise ratio of the image or/and on the basis of the recognized edge structure. Furthermore, the invention relates to an imaging plate scanner for carrying out such a method.

Abstract: The invention relates to a method and to system for producing blades (1) of a machine interacting with a fluid, in particular a fluid-driven machine, in particular a wind turbine, comprising an examination device (19) for determining geometric deviations (A, B, C, D, E, F) from a target shape for one or more shaped blades (1), a device (21) for determining a deviation evaluation of one or more determined geometric deviations from the target shape for each blade with respect to the aerodynamic and/or mechanical consequences thereof, a device (23) for assigning one or more corrective measures (100, 101, 102), each including an expenditure evaluation (100?, 101?, 102?), to one or more determined geometric deviations (A, B, C, D, E, F) from the target shape for each blade, and a linking device (24) for linking a deviation evaluation that was determined for one or more of the determined geometric deviations to the expenditure evaluation for one or more determined corrective measures and for determining the correct

Abstract: The invention relates to a method and to system for producing blades (1) of a machine interacting with a fluid, in particular a fluid-driven machine, in particular a wind turbine, comprising an examination device (19) for determining geometric deviations (A, B, C, D, E, F) from a target shape for one or more shaped blades (1), a device (21) for determining a deviation evaluation of one or more determined geometric deviations from the target shape for each blade with respect to the aerodynamic and/or mechanical consequences thereof, a device (23) for assigning one or more corrective measures (100, 101, 102), each including an expenditure evaluation (100?, 101?, 102?), to one or more determined geometric deviations (A, B, C, D, E, F) from the target shape for each blade, and a linking device (24) for linking a deviation evaluation that was determined for one or more of the determined geometric deviations to the expenditure evaluation for one or more determined corrective measures and for determining the correct

Abstract: An airbag module has a module housing that has an airbag deployment opening with a predetermined opening dimension. An airbag is arranged folded in the module housing, the airbag having a first wall and a second wall situated opposite from the first wall. At least one holding means is arranged in the airbag. The at least one holding means is arranged in the unfolded airbag in the region of the airbag deployment opening and is attached on the airbag but not attached to the module housing. The holding means joins the first and second walls in the region of the airbag deployment opening and limits a distance between the walls in the region of the airbag deployment opening.

Abstract: An airbag module has a module housing that has an airbag deployment opening with a predetermined opening dimension. An airbag is arranged folded in the module housing, the airbag having a first wall and a second wall situated opposite from the first wall. At least one holding means is arranged in the airbag. The at least one holding means is arranged in the unfolded airbag in the region of the airbag deployment opening and is attached on the airbag but not attached to the module housing. The holding means joins the first and second walls in the region of the airbag deployment opening and limits a distance between the walls in the region of the airbag deployment opening.

Abstract: 9-Substituted 2-(2-n-alkoxyphenyl)purin-6-ones are prepared by cyclizing correspondingly substituted imidazoles and derivatizing the purines thus obtained. The 9-substituted .sup.2 -(2-n-alkoxyphenyl)purin-6-ones can be employed as active compounds in medicaments, in particular in medicarnents for treatment of inflammations, thromboembolic diseases and cardiovascular diseases.

Abstract: 2,9-Disubstituted purin-6-ones are prepared by acylating correspondingly substituted aminoimidazoles in a first step and then cyclizing the product to the purine. The new 2,9-disubstituted purin-6-ones can be employed as active compounds in medicaments, in particular for the treatment of inflammations, thromboembolic and cardiovascular diseases and diseases of the urogenital system.

Abstract: 2,8-Disubstituted quinazolinones are prepared by first subjecting the quinazolinone basic skeleton to condensation by customary reactions and then introducing the desired substituents into the 8-position. The compounds are suitable as active compounds in medicaments, in particular for the treatment of inflammations, thromboembolic diseases and cardiovascular diseases.

Abstract: The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.

Abstract: Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl, andR.sup.5 completes a keto or ester group,and physiologically acceptable salts thereof.

Abstract: Indolesulphonamide-substituted dihydropyridines can be prepared by reaction of dihydropyridinecarboxylic acids with hydroxy-substituted indolesulphonamides, or by reaction of amino- or hydroxy-substituted dihydropyridines with indolesulphonamidecarboxylic acids. The indolesulphonamide-substituted dihydropyridines can be employed as active substances in medicaments for the treatment of cardiac, circulatory and thromboedabolic disorders.

Abstract: 4 Aminoaryldihydropyridines of the formula ##STR1## in which R.sup.1 is hydrogen or an organic radical, preferably methyl or ethyl,R.sup.2 is hydrogen, C.sub.1 -C.sub.5 - alkyl, --CN, --NH.sub.2, --CH.sub.2 or --CH.sub.2 OH, preferably methyl,R.sup.3 is hydrogen or alkyl, preferably hydrogen,Y is --CO-- or --SO.sub.2 --, andR.sup.4 is an organic radical, orY-R.sup.4 is hydrogen,and physiologically acceptable salts thereof, are circulation-active and effective for improving myocardial contractility, for raising blood pressure, for lowering blood sugar, for reducing mucosal swelling and for controlling the salt and fluid balance.

Abstract: Cardioactive dihydropyridines of the formula ##STR1## in which Y is ##STR2## A is H or CH.sub.3, B is --NH, --NH--CO--, --NH--CS--, --NH--COO--, --NH--SO.sub.2 --or --NH--CO--NH-- or --NH--CS--NH--, andR.sup.13 and R.sup.14 each independently is H or an organic radical,and salts thereof. The Y can be hydrolyzed off. The other radicals on the dihydropyridine moiety can also be varied.

Abstract: Hypertension and cardiac insufficiency can be controlled by 4-nitrophenyl-dihydropyridine amides of the formula ##STR1## in which X can be ethylene or the like,Y is pyridyl or --NR.sup.9 R.sup.10, andR.sup.9 and R.sup.10 each independently is hydrogenor an organic group, or together form a ring, and physiologically tolerated salts thereof. Compounds in which R.sup.5 and R.sup.6 are not aryl or aralkyl are new.

Abstract: Cardioactive dihydropyridines of the formula ##STR1## in which Y is ##STR2## A is H or CH.sub.3, B is --NH, --NH--CO--, --NH--CS--, --NH--COO--, --NH--SO.sub.2 --or --NH--CO--NH-- or --NH--CS--NH--, andR.sup.13 and R.sup.14 each independently is H or an organic radical,and salts thereof. The Y can be hydrolyzed off. The other radicals on the dihydropyridine moiety can also be varied.

Abstract: Circulation active dihydropyridine amides of the formula ##STR1## in which R.sup.6 represents a group of the formula --O--(CH.sub.2).sub.n --R.sup.10, --S--(CH.sub.2).sub.n --R.sup.10 --O--SO.sub.2 --(CH.sub.2).sub.n R.sup.10 or --O--CO--(CH.sub.2).sub.n --R.sup.10in whichn denotes 0 to 4,andR.sup.10 denotes cyclohexyl, aryl or a heterocyclic ring,and physiologically acceptable salts thereof.

Abstract: Circulation-active fluoromethoxyphenyldihydropyridines of the formula ##STR1## in which X stands for hydrogen or fluorine andR stands for straight-chain, branched or cyclic alkyl or alkenyl having 2 to 12 carbon atoms which can be interrupted by 1 to 2 oxygen and/or sulphur atoms in the chain, and which can be monosubstituted or polysubstituted(a) by hydroxyl, aryl having 6 to 12 carbon atoms, aryloxy having 6 to 12 carbon atoms, where the aryl radical is again substituted by alkyl having up to 4 carbon atoms, alkoxy having up to 4 carbon atoms or halogen, the substituents being identical or different, or(b) by carboxyl, alkoxycarbonyl having up to 6 carbon atoms, pyridyl, piperidyl, pyrimidyl, acyloxy having up to 7 carbon atoms, sulphamoyl, carbamoyl, halogen or cyano, the substituents being identical or different, or(c) by an amino group, where the amino group can carry one or two identical or different substituents from the group consisting of alkyl having up to 6 carbon atoms, benzyl, phenyl or acyl havi

Abstract: A benzylaminoaryl-dihydropyridinelactone compound of the formula (I) ##STR1## in which R.sup.1 represents hydrogen, halogen, cyano, nitro, C.sub.6 -C.sub.12 -aryl, C.sub.1 -C.sub.8 -alkyl, C.sub.1 -C.sub.8 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethoxy, di-C.sub.1 -C.sub.5 -alkylamino, C.sub.1 -C.sub.6 -alkoxycarboxyl or C.sub.1 -C.sub.6 -alkylsulphonyl,R.sup.2 represents hydrogen, or represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical having up to 10 carbon atoms which is optionally substituted by C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, C.sub.1 -C.sub.6 -alkylsulphonyl, halogen, cyano, hydroxyl, pyridyl, thienyl, pyrimidyl, piperidinyl, phenyl or an amino group, where the amino group carries two identical or different substituents from the series comprising C.sub.1 -C.sub.5 -alkyl, phenyl or benzyl,R.sup.3 represents C.sub.1 -C.sub.

Abstract: Circulation active nitrodihydropyridines of the formula ##STR1## in which R represents aryl which has 6 to 12 carbon atoms and can be substituted up to 4 times, identically or differently, by halogen, nitro, cyano, alkyl, alkoxy, alkylthio, in each case having up to 6 carbon atoms, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio, difluoromethylenedioxy, trifluoroethylenedioxy or tetrafluoroethylenedioxy or by benzyl, benzyloxy or benzylthio, each of which is optionally substituted by halogen, nitro, cyano, trifuoromethyl, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms, or represents a heterocycle which is optionally substituted by halogen, phenyl or alkyl having up to 4 carbon atoms and is from the group consisting of pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, pyridazinyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl, andn represents a number from 1 to 12,and physiologically acceptable salts thereof.

Abstract: Novel circulation-active cyclohexenecarboxylates of the formula ##STR1## in which R.sup.1 is an organic radical,R.sup.2 is an optionally substituted aryl radical,R.sup.3 is an optionally substituted alkyl or aryl radical,X and Y are --CN, --COR.sup.4, --SO.sub.2 R.sup.4, --COOR.sup.5, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 are various organic radicals.